Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV

A phase 3, randomized, double‐blind, placebo‐controlled study evaluating a single, patient‐initiated dose of amenamevir for recurrent herpes labialis

(2022) Makoto Kawashima et al.   JOURNAL OF DERMATOLOGY

A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections

(2021) Christian Gege et al.   Science Translational Medicine

Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2

(2021) Lauren A. Sadowski et al.   Viruses-Basel

Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model

(2021) Nadja Uhlig et al.   ANTIVIRAL RESEARCH

Resolution of herpes simplex virus reactivation in vivo results in neuronal destruction

(2020) Jessica R. Doll et al.   PLoS Pathogens

Herpes simplex virus: global infection prevalence and incidence estimates, 2016

(2020) Charlotte James et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Use of the Guinea pig model of genital herpes to evaluate vaccines and antivirals: Review

(2020) David I. Bernstein   ANTIVIRAL RESEARCH

Herpes Viruses and Senile Dementia: First Population Evidence for a Causal Link

(2018) Ruth F. Itzhaki et al.   JOURNAL OF ALZHEIMERS DISEASE

Neonatal herpes simplex virus infections

(2018) Swetha G. Pinninti et al.   SEMINARS IN PERINATOLOGY

Herpes Simplex Encephalitis: an Update

(2017) John W. Gnann et al.   Current Infectious Disease Reports

Approved Antiviral Drugs over the Past 50 Years

(2016) Erik De Clercq et al.   CLINICAL MICROBIOLOGY REVIEWS

Antiviral resistance in herpes simplex virus and varicella-zoster virus infections

(2016) Jocelyne Piret et al.   CURRENT OPINION IN INFECTIOUS DISEASES

De Novo Herpes Simplex Virus VP16 Expression Gates a Dynamic Programmatic Transition and Sets the Latent/Lytic Balance during Acute Infection in Trigeminal Ganglia

(2016) Nancy M. Sawtell et al.   PLoS Pathogens

Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection

(2014) Anna Wald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daily Acyclovir to Decrease Herpes Simplex Virus Type 2 (HSV-2) Transmission from HSV-2/HIV-1 Coinfected Persons: A Randomized Controlled Trial

(2013) Andrew Mujugira et al.   JOURNAL OF INFECTIOUS DISEASES

The herpes simplex virus type 1 latency associated transcript locus is required for the maintenance of reactivation competent latent infections

(2011) Richard L. Thompson et al.   JOURNAL OF NEUROVIROLOGY

Effect of ASP2151, a Herpesvirus Helicase-Primase Inhibitor, in a Guinea Pig Model of Genital Herpes

(2011) Kiyomitsu Katsumata et al.   MOLECULES

De Novo Synthesis of VP16 Coordinates the Exit from HSV Latency In Vivo

(2009) Richard L. Thompson et al.   PLoS Pathogens